Steve Spotts becomes chief commercial officer of Swift Biosciences; Integrated Diagnostics adds Jay Moyes as independent director; Qiagen supervisory board proposes Vera Kallmeyer and Elizabeth Tallett for election.
A number of prominent proteomics-based diagnostics developers were recipients of the grant and tax credit awards, which are being provided by the IRS through the Patient Protection and Affordable Care Act's Qualifying Therapeutic Discovery Project Program.
Paul Billings, Robert Wall, Cliff Reid, Michael Rubin, David Baltimore, Gregory Critchfield, David Barker, Jim Heath, Lee Hood, Patrizia Luchetta, Albert Luderer, Arnold Oronsky, Subra Suresh
The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
